Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Improved glycaemic control with fixed-ratio combination of insulin degludec and liraglutide

Diabetes patient injecting insulin

Source: Image Point Fr /

The DUAL trial found that rates of hypoglycaemia were lowest with liraglutide, highest with insulin degludec and intermediate with IDegLira

Basal insulin and glucagon-like peptide (GLP)-1 receptor agonists are individually effective for controlling blood glucose in patients with diabetes but are also associated with unwanted side effects.

A new fixed-ratio combination of insulin degludec, a basal insulin analogue, plus liraglutide, a GLP-1 analogue (IDegLira), has demonstrated better control of blood glucose than either drug given alone, and with no increase in hypoglycaemia.

Findings from the DUAL trial, reported in The Lancet Diabetes & Endocrinology (online, 2 September 2014), show that patients who took IDegLira (Xultophy) for 26 weeks experienced a significantly greater mean reduction in HbA1c (–1.9%) than patients taking either insulin degludec (–1.4%) or liraglutide (–1.3%)[1].

Rates of hypoglycaemia were lowest with liraglutide, highest with insulin degludec and intermediate with IDegLira.

IDegLira, a single, once-daily injectable, is expected to be authorised for use in Europe within months.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066433

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Diabetes patient injecting insulin

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.